Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 1 Completed 131 enrolled Celgene Corporation

NaSequentialOpen-labelTreatment

Summary

The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.

Timeline

Start: 2020-06-22
Primary completion: 2025-10-28
Completion: 2025-10-28

Publications

Rathkopf DE, Patel MR, Choudhury AD, Rasco D, Lakhani N, Hawley JE, Srinivas S, Aparicio A, Narayan V, Runcie KD, Emamekhoo H, Reichert ZR, Nguyen MH, Wells AL, Kandimalla R, Liu C, Suryawanshi S, Han J, Wu J, Arora VK, Pourdehnad M, Armstrong AJ. Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2025 Jan;36(1):76-88. doi: 10.1016/j.annonc.2024.09.005. Epub 2024 Sep 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CC-94676	Other / unclassified	400 mg	Oral
Subject	CC-94676	Other / unclassified	900 mg	Oral
Background	BMS-986410	Unknown	—	—
Background	GRIDEGALUTAMIDE	Small molecule	—	—

Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

Summary

Timeline

Publications

Drugs

Indications